IRMD vs. LIVN, WRBY, NVCR, LMAT, CNMD, ENOV, EYE, LQDA, TNDM, and CDRE
Should you be buying Iradimed stock or one of its competitors? The main competitors of Iradimed include LivaNova (LIVN), Warby Parker (WRBY), NovoCure (NVCR), LeMaitre Vascular (LMAT), CONMED (CNMD), Enovis (ENOV), National Vision (EYE), Liquidia (LQDA), Tandem Diabetes Care (TNDM), and Cadre (CDRE). These companies are all part of the "medical equipment" industry.
Iradimed vs. Its Competitors
Iradimed (NASDAQ:IRMD) and LivaNova (NASDAQ:LIVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, media sentiment, valuation, earnings, institutional ownership, analyst recommendations, risk and dividends.
Iradimed currently has a consensus target price of $72.00, suggesting a potential upside of 21.68%. LivaNova has a consensus target price of $59.29, suggesting a potential upside of 27.44%. Given LivaNova's higher probable upside, analysts clearly believe LivaNova is more favorable than Iradimed.
LivaNova received 148 more outperform votes than Iradimed when rated by MarketBeat users. Likewise, 69.80% of users gave LivaNova an outperform vote while only 65.58% of users gave Iradimed an outperform vote.
Iradimed has higher earnings, but lower revenue than LivaNova. LivaNova is trading at a lower price-to-earnings ratio than Iradimed, indicating that it is currently the more affordable of the two stocks.
Iradimed has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, LivaNova has a beta of 0.9, indicating that its stock price is 10% less volatile than the S&P 500.
Iradimed has a net margin of 26.26% compared to LivaNova's net margin of 1.91%. Iradimed's return on equity of 24.12% beat LivaNova's return on equity.
92.3% of Iradimed shares are owned by institutional investors. Comparatively, 97.6% of LivaNova shares are owned by institutional investors. 36.8% of Iradimed shares are owned by company insiders. Comparatively, 0.3% of LivaNova shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
In the previous week, LivaNova had 1 more articles in the media than Iradimed. MarketBeat recorded 4 mentions for LivaNova and 3 mentions for Iradimed. Iradimed's average media sentiment score of 1.81 beat LivaNova's score of 0.72 indicating that Iradimed is being referred to more favorably in the media.
Summary
Iradimed and LivaNova tied by winning 9 of the 18 factors compared between the two stocks.
Get Iradimed News Delivered to You Automatically
Sign up to receive the latest news and ratings for IRMD and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding IRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Iradimed Competitors List
Related Companies and Tools
This page (NASDAQ:IRMD) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy IRMD Stock Free IRMD Stock Alerts